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The human genome encodes 13 distinct 5-HT G-protein-coupled receptors (GPCRs). Drugs targeting 5-HT GPCRs are approved treatments for a diverse array of indications, includ-
ing obesity, migraine headaches, schizophrenia, anxiety and depres-
sion1,2. 5-HT receptors also frequently mediate serious drug side 
effects via unanticipated ‘off-target’ actions1,3. A notable example is 
the now-banned appetite suppressant fenfluramine, which exerts 
its potent anti-obesity actions by activating 5-HT2C receptors4. 
Fenfluramine was ultimately withdrawn from the market because 
of a high incidence of drug-induced valvular heart disease (VHD), 
which occurs as a result of off-target activation by fenfluramine and 
its active metabolite norfenfluramine at the closely related 5-HT2B 
receptor (5-HT2BR)5,6.
Several other medications, including the anti-migraine drugs 
methysergide and ergotamine5, the anti-parkinsonian medications 
pergolide and cabergoline7, and drugs that treat pituitary adenomas, 
also have potent off-target actions at 5-HT2BR, and they have also 
been withdrawn or their use severely restricted because of drug-
induced VHD1,5. Of note, both the VHD and fibrosis associated 
with carcinoid syndrome have been linked to 5-HT2BR activation8. 
Consequently, candidate medications are routinely screened for 
5-HT2B agonist activity before progressing to clinical trials9,10. Not
unexpectedly, 5-HT2B antagonists have been proposed as poten-
tial therapeutics for VHD and other fibrotic disorders, including
carcinoid syndrome11. Thus, understanding the action of drugs at
5-HT2BR is clearly important for future drug development.
5-HT2BR is a member of the 5-HT2 subfamily of 5-HT receptors,
which also includes 5-HT2A and 5-HT2C receptors. 5-HT2BR activa-
tion via Gq/11 induces phospholipase C activation, inositol phosphate 
(IP) accumulation, intracellular calcium release and protein kinase 
C activation1,2. 5-HT2BR also recruits β -arrestin2 (also known as 
arrestin-3; encoded by ARRB2 in humans) and downstream effector 
activation9,12,13. Drugs such as lysergic acid diethylamide (LSD) and 
ergotamine (ERG) prefer arrestin recruitment and are considered 
‘arrestin-biased agonists’9,12,13.
Over the past few years, there has been an explosion in avail-
able GPCR structural information, which has provided a molecular 
understanding of ligand recognition14, receptor dynamics and acti-
vation15, and ligand-mediated biased signaling16. To date, structures 
of three 5-HT receptors have been determined by X-ray crystal-
lography, those of the 5-HT1B17,18, 5-HT2B12, and 5-HT2C19 receptors, 
all in complex with the VHD-inducing anti-migraine drug ERG. 
For the 5-HT2B receptor, LSD-bound and ERG-bound structures 
are available and reveal that ergot ligands engage a presumed 
orthosteric binding pocket (OBP), which is likely shared with 
the endogenous ligand 5-HT12,13,17. Indeed, ERG and LSD engage 
regions outside this OBP, which we have termed the extended 
binding pocket (EBP). The OBP of 5-HT receptors shares certain 
features with the OBP exemplified by the β 2-adrenergic receptor 
(β 2AR)20,21, and it includes highly conserved and critical ligand con-
tacts between the amine nitrogen of the ligands and a highly con-
served aspartate in transmembrane domain 3 (TM3; for example, 
Asp3.32 in the Ballesteros–Weinstein numbering scheme22), as well as 
polar and aromatic contacts in TM5 and TM6, respectively. These 
interactions are thought to facilitate the stabilization of active23 and 
G-protein-bound24 conformational states.
Little is known, however, regarding the 5-HT receptor EBP, which 
encompasses extracellular portions of TM3 and TM7 and has been 
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proposed as a potential structural feature that may facilitate biased 
signaling2. Support for this hypothesis comes from analysis of the 
structure of LSD bound to 5-HT2BR, in which LSD stereo-selectively 
engages TM3 and TM7 to evoke potent β -arrestin2 recruitment13. 
Additional insights into the mechanisms of biased agonism have 
recently emerged, revealing a key ligand interaction between LSD 
and Leu209 in extracellular loop 2 (EL2), which increases ligand 
residence time at the receptor that contributes to enhanced time-
dependent β -arrestin2 recruitment13. Additionally, both TM5 and 
the EL2 regions have recently been exploited for biased ligand 
design at aminergic GPCRs25; it is unclear how biased activation 
occurs via contact with these regions of the receptor.
A clearer understanding of how ligand interactions with key 
binding pocket residues lead to the stabilization of active or inac-
tive states will facilitate the design of agonist, biased agonist and 
antagonist drugs. The available structures are with a single ligand 
type (either agonist or antagonist). In instances where agonist and 
antagonist structures are available, the ligand chemotypes are struc-
turally diverse (for example, β 2AR, adenosine 2A, the μ and κ opi-
oid receptors, and others16,26). Such limitations make it difficult to 
leverage existing GPCR structural information for structure-guided 
drug design.
Here we identified key residues responsible for 5-HT2BR activa-
tion by comparing the binding modes of chemically similar ago-
nists and antagonists at 5-HT2BR. Notably, we were able to compare 
the binding mode of methylergonovine with that of its parent anti-
migraine drug, methysergide, which differs by a single methyl sub-
stituent. To illuminate antagonism, we compared the binding mode 
of the antagonist lisuride to that of the agonist LSD, which differs 
by only stereochemistry and an additional nitrogen atom. Finally, 
we elucidate biased signaling and subtype selectivity by clarifying 
the binding mode of the selective 5-HT2BR antagonist LY266097. 
These insights should accelerate the design of safer and more effec-
tive medications.
Results
Structural insights into a 5-HT2B activation mechanism. 
Methysergide is rapidly N-demethylated in vivo to methylergono-
vine, which is the major active metabolite that mediates methyser-
gide’s anti-migraine actions in vivo27. Unlike methysergide, which is 
a 5-HT2BR antagonist, methylergonovine is a potent 5-HT2BR ago-
nist6 responsible for methysergide-induced VHD5. Because methy-
sergide differs from methylergonovine by a single ‘–CH3’ moiety 
(Fig. 1a), the pair represents a key ligand set to gain insight into 
the ligand-based structural features responsible for 5-HT2BR effi-
cacy. Other unsubstituted N(1)-H ligands, such as methylergono-
vine, LSD and ERG, are Gq partial agonists (Fig. 1b). By contrast, the 
N(1)-methyl or alkyl ergoline ligands methysergide (Fig. 1b) and 
LY215840 (Supplementary Fig. 1a) are 5-HT2BR antagonists.
To identify residues critical for methylergonovine’s agonism, 
we obtained the crystal structure of the 5-HT2BR–methylergo-
novine complex at a resolution of 2.9 Å (Fig. 1c and Table 1). 
Methylergonovine forms a salt bridge with Asp1353.32 in the pre-
sumed orthosteric site, and the ergoline ring system forms an 
edge-to-face π -π stack with residues Phe3406.51 and Phe3416.52 in 
TM6—interactions that are commonly observed in aminergic20,23 
and 5-HT13,17,19 structures. The binding mode of methylergono-
vine, when compared with those of LSD and ergotamine, bound 
to 5-HT2BR revealed a subtly different positioning of the indole 
N(1)-H toward TM5 residues, with ERG being the deepest toward 
Ala2255.46 and LSD being the shallowest toward the backbone of 
Gly2215.42 (Supplementary Fig. 1b). This differential positioning 
is likely caused by a rotation around the axis of the ionic interac-
tion between Asp3.32 and the protonated ergoline amine group13. 
Similar to ERG, N(1)-H of methylergonovine points toward resi-
dues Ala2255.46 and Thr1403.37 (Fig. 1d and Supplementary Fig. 1c). 
Although the density of N(1)-H of methylergonovine was not 
resolved at 2.9-Å resolution, this hydrogen likely resides between 
residues Ala2255.46 and Thr1403.37.
To determine whether residues Thr1403.37 and Ala2255.46 were 
involved in methylergonovine’s agonism, we mutated the sequences 
encoding residues Thr1403.37 and Ala2255.46. Thr140Ala3.37 and 
Thr140Val3.37 substitutions substantially diminished methylergo-
novine’s agonism (Fig. 1e) and binding affinity (Supplementary 
Table 1), despite similar surface expression levels relative to the 
wild-type receptor (Supplementary Fig. 1d). Although there was 
not an optimal angle for a hydrogen bonding between N(1)-H and 
residue Thr1403.37 in the 5-HT2BR–methylergonovine structure 
(Supplementary Fig. 1e), the close distance suggests that at least 
an electrostatic interaction (van der Waals, vdW) between residue 
Thr1403.37 and N(1)-H may occur during activation. Indeed, 5-HT, 
which also contains an N(1)-H on the indole, displayed weak Gq 
activity at Thr140Ala3.37 and Thr140Val3.37 mutants (Supplementary 
Fig. 1f), indicating that Thr1403.37 is essential for receptor activa-
tion. To recapitulate a favorable electrostatic interaction, we created 
Thr140Ser3.37 mutant receptor and found that methylergonovine’s 
Gq agonism (Fig. 1e) and binding affinity (Supplementary Table 1) 
were spared. By contrast, the substitutions Ala225Ser5.46 and 
Ala225Gly5.46 did not substantially affect methylergonovine’s Gq 
agonism (Fig. 1f) or binding affinity (Supplementary Table 1), and 
they spared 5-HT Gq activity (Supplementary Fig. 1g). Thus, methy-
lergonovine’s interaction with Thr1403.37 is critical for 5-HT2BR acti-
vation.
Structure of a 5-HT2BR Ala225Gly5.46 mutant designed to be 
activated by methysergide. We next sought to understand how 
the N(1)-methyl of methysergide causes 5-HT2BR antagonism. We 
hypothesized that methysergide’s N(1)-methyl would either lack 
interaction with Thr1403.37 and/or cause a steric clash with Ala2255.46. 
Methysergide failed to demonstrate any measurable Gq agonist 
activity with a Thr140Val3.37 mutant, where it was expected that the 
valine and N(1)-methyl could form additional vdW interactions 
to lead to activation (Fig. 2a). By contrast, methysergide demon-
strated potent Gq partial agonist activity (Fig. 2a and Supplementary 
Fig. 2a) with the Ala225Gly5.46 mutant, which we hypothesized to 
introduce more bulk tolerance for methysergide’s N(1)-methyl—a 
notion consistent with TM5 engagement appearing to be important 
for G-protein-dependent agonism25.
To test this hypothesis, we obtained a structure for the 
5-HT2BR(Ala225Gly5.46)–methysergide complex at 3.1-Å resolution
(Fig. 2b, Table 1 and Supplementary Fig. 2b,c). Similar to what was
seen in the structure of the 5-HT2BR–methylergonvine complex,
methysergide made conserved contacts with Asp1353.32, Phe3406.51
and Phe3416.52. Of note, methysergide’s N(1)-methyl was pointed
down into the space at the mutant Gly2255.46 residue. As predicted,
removal of a methyl substituent from Ala2255.46 to form Gly2255.46
created ‘space’ (for example, bulk tolerance) for the methysergide’s
N(1)-methyl at TM5 (Fig. 2c).
To obtain further insights into methysergide’s engagement at 
TM5, we compared the 5-HT2BR(Ala225Gly5.46)–methysergide 
structure to that of inactive-state β 2AR bound to the antagonist ICI-
118,55128. ICI-118,551, like methysergide, also contains a methyl 
substitution on its core scaffold that appears to sterically ‘push’ 
against residue Ser2075.46 in TM5. Alignment of both structures 
revealed a 1–2 Å shift in TM5, in which the extracellular side of 
TM5 moved closer to methysergide in the 5-HT2BR(Ala225Gly5.46)–
methysergide structure, whereas ICI-118,551 precluded TM5 move-
ment via its methyl substituent in the β 2AR–ICI-118,551 structure 
(Fig. 2d). Notably, this TM5 shift is also observed in the nanobody-
stabilized active state of β 2AR23. Alignment of the structure of the 
β 2AR–ICI-118,551 complex with that of the nanobody-stabilized 
active state of β 2AR revealed that ICI-118,551 precludes this inward 
TM5 movement via the methyl substituent (Supplementary Fig. 2d). 
Our results thus reveal that residues Thr1403.37 and Ala2255.46 are 
essential for activation.
Structural basis for a 5-HT2B activation mechanism via the 
extended binding pocket. We next focused on the role of the EBP 
in receptor activation. We have previously shown that LSD’s dieth-
ylamide, which is key for LSD’s potent hallucinogenic effects29, con-
tacts TM3 and TM7 within the EBP13. Furthermore, we found that 
recognition of LSD in this region is stereo-selective, as LSD’s potent 
agonism was recapitulated by only the (S,S)-azetidide stereoisomer, 
a conformationally restricted diethylamide stereoisomer of LSD13. 
Less clear, however, is the effect of opposing stereochemistry at 
the C8 position in antagonist versus agonist recognition. Here we 
sought to examine other ergoline ligands, such as lisuride, which 
has the same ergoline core scaffold as LSD yet possesses an (S)-
diethylurea (Fig. 3a) and is a potent 5-HT2BR antagonist30 (Fig. 3b).
To identify the structural basis for lisuride’s antagonism, we 
solved the structure of the 5-HT2BR–lisuride complex to a resolution 
of 3.1 Å (Fig. 3c, Table 1 and Supplementary Fig. 3a,b). Alignment of 
the 5-HT2BR–LSD and 5-HT2BR–lisuride structures showed similar 
binding poses in the OBP, where the indole N(1)-H of both LSD 
and lisuride formed a hydrogen bond with the carbonyl backbone 
at residue Gly2215.42 in TM5 (Supplementary Fig. 3c). Comparison 
of these poses at the OBP could not entirely explain the difference 
in pharmacological activity between LSD and lisuride. By contrast, 
comparison of the EBP poses revealed that the (S)-diethylurea of 
lisuride was exclusively wedged between residues Trp1313.28 and 
Leu1323.29 in a hydrophobic stack, making minimal contact with 
TM7 residues. This resulted in 1.2 Å less contraction of the binding 
pocket between residues Trp1313.28 and Leu3627.35 as compared to 
the distance in the LSD-bound structure. By contrast, LSD’s binding 
pose, in which the diethylamide contacts residue Leu3627.35 in TM7 
(Fig. 3c), exhibited a more contracted binding pocket. This unex-
pected difference in binding pose likely explains lisuride’s lack of 
agonism at 5-HT2BR, whereas contact with TM7 residue Leu3627.35 
in the EBP appears essential for LSD’s agonism.
To test the hypothesis that ligand contact with TM7 in the EBP 
facilitates 5-HT2BR activation, we made substitutions at residue 
Leu3627.35, which is the closest residue in proximity to lisuride’s 
diethylurea in TM7, to facilitate an interaction between lisuride 
and TM7. Consistent with our hypothesis, substitution of Leu3627.35 
with asparagine (Leu362Asn7.35), which we predicted would result 
in formation of a hydrogen bond with the backbone of lisuride’s 
diethylurea moiety, led to Gq partial agonism (half-maximal effec-






























































































































































Fig. 1 | Structural insights into a 5-HT2B activation mechanism. a, Structure–activity relationship of 5-HT2BR ergoline ligands comparing unsubstituted 
N(1)-H ligands (red) (such as 5-HT, ergotamine and methylergonovine) to N(1)-methyl methysergide (blue). b, 5-HT2BR Gq calcium flux activity by 5-HT 
(black; EC50 =  1.4 nM; Emax =  100%) or methylergonovine (red; EC50 =  31 nM; Emax =  66%) and lack of agonist activity by methysergide (blue, closed circles). 
Methysergide acts as a competitive antagonist (blue open circles; half-maximal inhibitory concentration (IC50) =  2.4 nM) in response to 5-HT. c, Structure 
of methylergonovine (blue) at 5-HT2BR (green) with 2D ligand plots of nearby residues (in single-letter designations) (PDB 6DRY). d, Close-up view of 
the methylergonovine binding pose in the binding pocket highlighting Asp1353.32 (D1353.32) interacting with the charged nitrogen of methysergide and 
the indole N(1)-H interacting with both Thr1403.37 (T1403.37) and Ala2255.46 (A2255.46) in the OBP. e, Methylergonovine Gq-mediated calcium flux agonist 
activity with Thr140Ala3.37 (red), Thr140Val3.37 (blue) and Thr140Ser3.37 (green) mutants (EC50 =  18 nM; Emax =  64%) relative to wild-type (WT) 5-HT2BR 
(black; EC50 =  19 nM; Emax =  66%). f, Methylergonovine Gq-mediated calcium flux agonist activity in the Ala225Ser5.46 (red; EC50 =  15 nM; Emax =  58%) and 
Ala225Gly5.46 (blue; EC50 =  12 nM; Emax =  55%) mutants relative to wild-type 5-HT2BR (black; EC50 =  23 nM; Emax =  64%). Data in b, e and f represent the 
mean ±  s.e.m. from n =  3 independent experiments, each performed in triplicate. Source data are available online.
substituted Leu3627.35 with either phenylalanine (Leu362Phe7.35) or 
tyrosine (Leu362Tyr7.35), which could facilitate either a hydropho-
bic-aromatic interaction (phenylalanine or tyrosine) or a hydrogen 
bond (tyrosine) with the diethylurea of lisuride. With both mutants, 
lisuride was a potent partial agonist, with EC50 values as low as 77 nM 
(Fig. 3d) for the Leu362Phe7.35 mutant, a potency comparable to that 
of LSD with wild-type 5-HT2BR (EC50 = 40 nM, Emax = 82%; Emax = 
% maximum efficacy compared with full agonist). Substitution of 
Leu3627.35 with alanine (Leu362Ala7.35) impaired LSD’s Gq agonist 
potency by tenfold (EC50 = 401 nM, Emax = 79%; Fig. 3e), without 
altering 5-HT2BR surface expression levels (Supplementary Fig. 3d). 
Taken together, our results showing that LSD and lisuride occupy 
the OBP in a similar fashion yet exhibit different poses in the 
EBP indicate that ligand engagement with TM7, specifically with 
Leu3627.35, leads to an auxiliary mechanism of agonist activation via 
the EBP (Fig. 3f).
Divergent actions on β-arrestin recruitment by OBP versus EBP 
mutations. We previously reported that ergolines, such as ERG 
and LSD, display a preference for β -arrestin2 recruitment over Gq-
mediated calcium flux at 5-HT2BR12 and that LSD’s recruitment of 
β -arrestin2 appears to be time dependent and a product of its slow 
off-rate from 5-HT2BR13. A key structural motif identified for LSD’s 
potent β -arrestin2 recruitment is extracellular loop 2 (EL2); how-
ever, other regions of the binding pocket that lead to β -arrestin2 
recruitment at this receptor remain unexplored. Here we examined 
the roles of the EBP versus OBP regions for 5-HT2BR β -arrestin2 
recruitment.
First, we examined the OBP mutants that were critical for Gq 
activity for methylergonovine and methysergide (at Thr1403.37 and 
Ala2255.46, respectively). With the Thr140Ala3.37 mutant, methy-
lergonovine failed to recruit β -arrestin2 (Fig. 4a), indicating that 
the Thr140Ala3.37 substitution disrupts both Gq and β -arrestin2 
agonism. Similarly, the Ala225Gly5.46 substitution, which restores 
methysergide’s Gq agonism, also restored methysergide’s β -arrestin2 
recruitment (Fig. 4b). These results indicate that OBP activation via 
Thr1403.37 and Ala2255.46 leads to equal contributions for Gq activa-
tion and β -arrestin2 recruitment, as observed for the endogenous 
ligand 5-HT (Supplementary Fig. 4a,b).
Unexpectedly, the EBP Leu362Phe7.35 substitution, which 
restored lisuride’s Gq agonism, did not restore lisuride’s β -arres-
tin recruitment agonism (Fig. 4c). Although the Leu362Phe7.35 
substitution did not affect LSD’s Gq agonism, it abolished LSD’s 
β -arrestin recruitment (Fig. 4d). Notably, impairment of β -arrestin2 
recruitment by substitution at Leu3627.35 appeared to be dependent 
on the type of substitution—Leu362Phe7.35 showed the weakest 











Space group C2221 C2221 C2221 C2221
Cell dimensions
 a, b, c (Å) 59.7, 119.5, 171.0 59.1, 119.3, 172.6 59.4, 118.6, 168.2 59.5, 120.1 169.5
 α , β , γ (°) 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90
Resolution (Å) 30.0–2.9 (2.99–2.90)a 30–3.1 (3.19–3.10) 30.0–3.1 (3.17–3.10) 30.0–3.2 (3.29–3.20)
Rmerge (%) 15.7 (71.8) 16.3 (84.5) 12.2 (95.0) 15.9 (128.0)
I/σ(I) 7.7 (1.4) 8.7 (1.2) 10.9 (1.1) 9.8 (1.2)
CC1/2 98.0 (56.0) 98.0 (61.2) 99.6 (46.2) 99.4 (39.1)
Completeness (%) 91.8 (81.1) 93.4 (94.4) 97.1 (97.1) 93.5 (96.5)
Redundancy 2.6 (2.1) 3.3 (3.3) 4.4 (4.3) 3.8 (3.8)
Refinement
Resolution (Å) 2.9 3.1 3.1 3.2
No. reflections 12,436 10,595 10,679 9,725
Rwork/Rfree 23.5/27.1 22.5/26.3 24.3/28.6 22.3/26.4
No. atoms
5-HT2BR 2,200 2,174 2,144 2,177
BRIL 733 622 506 637
Ligand 25 26 25 26
Lipid and other 82 79 53 54
B factors
5-HT2BR 72.5 73.8 81.7 82.7
BRIL 87.1 91.1 135.3 146.5
Ligand 70.2 57.7 77.1 81.7
Lipid and other 90.5 84.7 84.6 100.0
R.m.s. deviations
Bond lengths (Å) 0.003 0.004 0.002 0.002
Bond angles (°) 0.49 0.61 0.76 0.48
aValues in parentheses are for the highest-resolution shell. bThe number of crystals is 11. cThe number of crystals is 13. dThe number of crystals is 11. eThe number of crystals is 8.
recruitment for β -arrestin with some restoration by Leu362Tyr7.35 
(Supplementary Fig. 4c).
Further analysis of the Leu362Phe7.35 mutant revealed no defi-
cits in Gq function as assessed by PI hydrolysis (Supplementary 
Fig. 4d) or Gq/γ1 dissociation, measured by bioluminescence reso-
nance energy transfer (BRET; Supplementary Fig. 4e). By contrast, 
the Leu362Phe7.35 substitution attenuated LSD’s time-dependent 
recruitment of β -arrestin (Supplementary Fig. 4f), as observed previ-
ously for the EL2 Leu209Ala substitution13. Accordingly, we directly 
measured LSD’s dissociation rate with the Leu362Phe7.35 mutant, 
observing a > 10-fold faster dissociation rate than for wild-type 
5-HT2BR (Fig. 4e). Thus, the Leu362Phe7.35 substitution decreases
β -arrestin2 recruitment by accelerating dissociation, thereby con-
tributing to β -arrestin2 recruitment. Taken together, ligand recog-
nition in the OBP results in equivalent Gq and β -arrestin2 activity, 
whereas ligand recognition in the EBP, specifically at TM7, results in 
either Gq or β -arrestin2 recruitment activity and divergent effects on 
ligand bias (Fig. 4f).
Structure of 5-HT2BR–LY266097 reveals TM7 as a trigger for 
biased signaling. Finally, we explored non-ergoline antagonists 
with distinct scaffolds to determine whether they displayed similar 
binding modes that were shared with other 5-HT2BR antagonists. 
Although lisuride is a 5-HT2BR antagonist, it lacks selectivity for 
5-HT2BR, as is commonly observed for many ergolines19. LY266097, 
however, is a purported selective 5-HT2BR antagonist31 that contains 
a distinct tetrahydro-β -carboline pharmacophore, and determining
the binding mode of LY266097 could illuminate novel structural
determinants of 5-HT2BR selectivity.
Accordingly, we crystallized LY266097 in a BRIL-fused 5-HT2BR 
(BRIL; thermostabilized apocytochrome b562RIL) and solved the 
5-HT2BR–LY266097 structure at 3.2-Å resolution (Fig. 5a, Table 1
and Supplementary Fig. 5a,b). Analysis of LY266097’s binding pose
revealed that the tetrahydro-β -carboline core scaffold was oriented
in the OBP with the charged nitrogen engaging Asp1353.32 in TM3
and the tetrahydro-β -carboline core engaging residues Phe3406.51
and Phe3416.52 in a π -π aromatic stack. Unexpectedly, when we
compared the binding modes of LY266097 and lisuride in the
EBP, we observed that LY266097’s 2-chloro-3,4-dimethoxybenzyl
substituent was oriented much closer to TM7 than that of lisuride
(Fig. 5b,c). On the basis of our previous finding that TM7 appears
to be important for biased agonism, we hypothesized that LY266097
should show preference for either Gq or β -arrestin2 activity. We
found LY266097 to be a modest Gq partial agonism without detect-
able β -arrestin2 activity (Fig. 5d) and confirmed LY266097’s Gq par-
tial agonism in an additional assay of Gq function via PI hydrolysis
(Supplementary Fig. 5c). We also tested LY266097 in an orthologo-
























































































Fig. 2 | Structure of a 5-HT2BR(Ala225gly5.46) mutant designed to be activated by methysergide. a, Left, design of the mutation to convert methysergide 
into an agonist by accommodating the N(1)-methyl (blue) with vdW interactions by Thr140Val3.37 or with space by Ala225Gly5.46. Right, 5-HT2BR 
methysergide Gq-mediated calcium flux activity with wild-type 5-HT2BR (black) and the Thr140Val3.37 (blue) and Ala225Gly5.46 (green) mutants 
(EC50 =  12 nM; Emax =  54%). Data represent the mean ±  s.e.m. from n =  3 independent experiments, performed in triplicate. Source data are available 
online. b, Structure of the 5-HT2BR(Ala225Gly5.46) mutant (blue) in complex with methysergide (purple), indicating that N(1)-methyl is positioned toward 
residues Thr1403.37 and Ala2255.46 in the OBP, which is also illustrated in the 2D ligand plot of nearby residues (PDB 6DRZ). c, Space-filling comparison 
of the 5-HT2BR–methylergonovine and the 5-HT2BR(Ala225Gly5.46)–methysergide structures indicating that the Ala225Gly5.46 mutant creates space to 
accommodate methysergide’s N(1)-methyl to achieve a similar pose as seen in the 5-HT2BR–methylergonovine structure. d, Comparison of the binding 
poses of the 5-HT2BR(Ala225Gly5.46)–methysergide structure to that of β 2AR (green) in complex with the inverse agonist ICI-118,551 (orange), indicating a 
1- to 2-Å shift difference in TM5 commonly observed in active versus inactive structures.
β -arrestin2 recruitment in real time monitored across specific time 
points. At no tested time point did LY266097 display β -arrestin2 
recruitment (Supplementary Fig. 5d); instead, it displayed potent 
β -arrestin2 antagonism (Supplementary Fig. 5e). These results 
 indicate that LY266097 has a bias toward Gq.
On the basis of our previous results with lisuride and the 
Leu362Phe7.35 mutant, we hypothesized that the extent of Gq 
agonism by LY266097 is determined by ligand contact between 
2-chloro-3,4-dimethoxybenzyl and Leu3627.35. To confirm that
LY266097’s contact with TM7 resulted in selective Gq activa-
tion, we tested LY266097 with the Leu362Phe7.35 mutant, which
was previously found to restore lisuride’s Gq agonist activity. As
expected, LY266097’s Gq agonist activity was abolished with the
Leu362Phe7.35 mutant (Fig. 5e), suggesting that the bulkiness of
the phenylalanine in the Leu362Phe7.35 mutant sterically clashed
with the 2-chloro-3,4-dimethoxybenzyl moiety, resulting in a
lack of agonism. To provide additional evidence that TM7 influ-
ences activation via strict steric requirements, we synthesized
analogs of LY266097 that lacked either a 2-chloro or a 3,4-dime-
thoxy substituent on the benzyl moiety, which would be expected
to show less TM7 interaction. We found a substituent-dependent
decrease in Gq-mediated agonist potency, with the unsubstituted
benzyl analog showing no detectible Gq agonist activity, indicat-
ing that the substitution pattern to LY266097’s scaffold conferred 
Gq agonism (Fig. 5f).
Similar to methysergide, LY266097 contains a methyl substituent 
on the tetrahydro-β -carboline scaffold that appears to ‘push’ on TM5 
at position Gly2215.42 (Fig. 5g), a key residue implicated in confer-
ring 5-HT2 subtype selectivity19. To determine whether LY266097’s 
methyl substituent was in part responsible for Gq partial agonism, 
we synthesized a des-methyl analog of LY266097 and found that 
it was nearly a full agonist (EC50 = 20 nM; Emax = 93%; Fig. 5h). 
These results suggest that the methyl substituent on LY266097 and 
its interaction with TM5 impair agonism.
Discussion
Here leveraged by four new 5-HT2B crystal structures, including the 
structure of a mutant receptor (Ala225Gly5.46) designed to switch a 
ligand’s efficacy, we provide a comprehensive structural analysis of 
ligand-specific contacts that lead to GPCR activation. Notably, this 
study not only identifies mechanisms of 5-HT GPCR activation via 
the orthosteric site, but also identifies important determinants of 
β -arrestin recruitment via the EBP, thereby illuminating determi-






















































































































































Fig. 3 | Structural basis for a 5-HT2B activation mechanism via the extended binding pocket. a, Comparison of the chemical structures of LSD and lisuride. 
LSD’s (R)-diethylamide (purple) and lisuride’s (S)-diethylurea (blue) lead to 5-HT2BR agonism and antagonism, respectively. b, 5-HT2BR Gq-mediated 
calcium flux activity. LSD shows Gq partial agonist activity (purple; EC50 =  40 nM; Emax =  82%), whereas lisuride lacks agonist activity (blue, closed circles). 
Lisuride instead shows competitive antagonism (blue, open circles; IC50 =  25 nM). c, Structure of lisuride (blue) at 5-HT2BR (light blue) in comparison to 
LSD (purple) bound to 5-HT2BR (green), showing lisuride’s (S)-diethylurea wedged between TM3 residues Trp1313.28 and Leu1323.29 and making no contact 
with TM7 Leu3627.35 (PDB 6DRX). d, Lisuride Gq-mediated calcium flux activity for the Leu362Asn7.35 (green; EC50 =  395 nM; Emax =  41%), Leu362Tyr7.35 
(orange; EC50 =  465 nM; Emax =  69%) and Leu362Phe7.35 (purple; EC50 =  77 nM; Emax =  60%) mutants. e, LSD Gq-mediated calcium flux activity for the 
Leu362Alal7.35 mutant (red; EC50 =  340 nM; Emax =  67%) relative to wild-type 5-HT2BR (purple; EC50 =  37 nM; Emax =  79%). Data in b, d and e represent the 
mean ±  s.e.m. from n =  3 independent experiments, performed in triplicate. Source data are available online. f, Schematic illustrating that ligand contact 
with residue Leu3627.35 in TM7 in the EBP leads to 5-HT2BR activation.
Our results with the 5-HT2BR–methylergonovine and 
5-HT2BR(Ala225Gly5.46)–methysergide structures illuminate an
orthosteric activation mechanism that occurs via ligand engagement
with residues Thr1403.37 and Ala2255.46. Although residue Ala2255.46
has been implicated as an important determinant of activation in
β -adrenergic receptors21,32, the role of the highly conserved Thr1403.37
residue is less understood. In fact, crystallographic evidence that
shows direct ligand engagement with residue Thr1403.37 in TM3 is
scarce. In rhodopsin, however, the β -ionone ring of retinal, which is
critical for receptor activation, is directly engaged with the Glu1223.37
residue. Retinal interaction with Glu1223.37 has been posited to lead
to disruption of a hydrogen bond between Glu1223.37 and His2115.46,
which causes an inward rotation of TM5, transducing disruption of
the ionic lock between the intracellular portions of TM3 and TM633. 
Although here ligand engagement with Thr1403.37 appears to involve 
either a hydrogen bond or an electrostatic interaction, it remains 
to be seen whether this ligand contact occurs frequently with other 
ligands or whether its role is more indirect (and in concert with resi-
due Ala2255.46) in the activation process, especially considering that 
residue Thr1403.37 is highly conserved across aminergic GPCRs. Our 
results do emphasize that ligand engagement with residue Ala2255.46 
and TM5 movement is important for an orthosteric mechanism of 
class A aminergic GPCRs—both regions highly conserved in aminer-
gic GPCRs that we have previously exploited to design biased ligands25.
To our knowledge, our results with the 5-HT2BR–lisuride struc-
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Fig. 4 | Divergent actions on β-arrestin2 recruitment by OBP versus eBP mutations. a, Left, methylergonovine Gq-mediated calcium flux comparing 
the Thr140Ala3.37 mutant (red) to wild-type 5-HT2BR (black; EC50 =  21 nM). Right, β -arrestin2 recruitment comparing the Thr140Ala3.37 mutant (red) to 
wild-type 5-HT2BR (black; EC50 =  1.2 nM). b, Left, methysergide Gq-mediated calcium flux comparing the Ala225Gly5.46 mutant (green; EC50 =  33 nM) to 
wild-type 5-HT2BR (black). Right, β -arrestin2 recruitment comparing the Ala225Gly5.46 mutant (green; EC50 =  1.7 nM) to wild-type 5-HT2BR (black). c, Left, 
lisuride Gq-mediated calcium flux comparing the Leu362Phe7.35 mutant (purple; EC50 =  65 nM) to wild-type 5-HT2BR (black). Right, β -arrestin2 recruitment 
comparing the Leu362Phe7.35 mutant (purple) to wild-type 5-HT2BR (black). d, Left, LSD Gq-mediated calcium flux comparing the Leu362Phe7.35 mutant 
(purple; EC50 =  40 nM) to wild-type 5-HT2BR (black; EC50 =  42 nM). Right, β -arrestin2 recruitment comparing the Leu362Phe7.35 mutant (purple) to 
wild-type 5-HT2BR (black; EC50 =  0.97 nM). Data in a–d are expressed as fold change relative to basal levels and represent the mean ±  s.e.m. from n =  3 
independent experiments, performed in triplicate. e, LSD dissociation comparing wild-type 5-HT2BR (black; koff =  0.015 min−1) to the Leu362Phe7.35 mutant 
(purple; koff =  0.240 min−1). Data represent the percentage specific binding, indicating the mean ±  s.e.m. from n =  3 independent experiments, performed 
in duplicate. f, Schematic comparing the location of the EBP residues Leu209EL2 and Leu3627.35 (purple), which contribute to either Gq or β -arrestin2 
recruitment preference, to the location of OBP residues Thr1403.37 and Ala2255.46 (green), which have equal contributions to Gq activity and β -arrestin2 
recruitment. Source data for the graphs are available online.
via the EBP, specifically via ligand contact with TM7 at residue 
Leu3627.35. This extended binding region of the receptor is less con-
served, allowing for ligand-specific engagement of non-conserved 
residues, and it likely explains the diverse pharmacological action 
that results from ligand-specific substituents that project from the 
core scaffold, as in the case of LSD, where the diethylamide projects 
away from the core ergoline scaffold. Of note, the same residues, 
Trp1313.28, Leu1323.29 and Leu3627.35, which are also involved in rec-
ognition of LSD’s diethylamide and lisuride’s diethylurea, compose 
part of the allosteric site of muscarinic receptors34. This suggests 
that ergoline ligands, such as LSD, access a potential allosteric site, 
leading to a diverse pharmacological profile (for example, antago-
nism or biased agonism). However, it remains to be seen whether 
bona fide allosteric modulators can selectively target the EBP of 
5-HT receptors, leading to bias.
Further study of the structural dynamics that lead to activation,
either via the OBP or EPB, is needed to clarify trigger motifs (for 
example, NPxxY, P-I-F, DRY) involved in either balanced or biased 
activation. Although BRIL-fusion 5-HT2BR structures adopt an 






































































































































































Fig. 5 | Structure of the 5-HT2BR–Ly266097 complex reveals TM7 as a trigger for biased signaling. Structure of 5-HT2BR in complex with LY266097 
reveals determinants of ligand bias via TM7. a, 5-HT2BR (orange) in complex with LY266097 (green) with a 2D ligand plot of nearby residues (PDB 6DS0). 
b, View from the top of the receptor showing that the 2-chloro-3,4-dimethoxybenzyl substituent of LY266097 is oriented in close proximity to residue 
Leu3627.35 in TM7. c, Alignment of the 5-HT2BR–LY266097 and 5-HT2BR–lisuride structures showing that LY266097’s 2-chloro-3,4-dimethoxybenzyl 
substituent is within 3.3 Å of Leu3627.35, whereas lisuride’s (S)-diethylurea is further away, at 6.3 Å from Leu3627.35. d, Profiling of LY266097 for ligand bias 
showing Gq partial agonist activity (red closed circles; EC50 =  37 nM; Emax =  62%) and partial antagonist activity (red open circles; IC50 =  78 nM), but no  
β -arrestin2 recruitment activity (blue). e, LY266097 Gq-mediated calcium flux activity comparing the Leu362Phe7.35 mutant (red) to wild-type 5-HT2BR 
(black; EC50 =  41 nM; Emax =  54%). f, Gq-mediated calcium flux activity of benzyl-substituted LY266097 analogs 3,4-diMeOBenzyl (blue; EC50 =  24 nM; 
Emax =  46%), 2-Clbenzyl (orange; EC50 =  35 nM; Emax =  28%) and unsubstituted benzyl (red). g, 5-HT2BR–LY266097 structure showing that the methyl 
substituent on the tetrahydro-β -carboline scaffold interacts with the 5-HT2-specific residue Gly2215.42. h, Gq-mediated calcium flux activity of a des-methyl 
LY266097 analog (purple; EC50 =  20 nM; Emax =  93%) results in nearly full agonist activity as compared to 5-HT (black; EC50 =  0.7 nM) or LY266097 (red; 
EC50 =  41 nM; Emax =  54%). Data in d–f and h represent the mean ±  s.e.m. from n =  3 independent experiments, performed in triplicate. Source data are 
available online.
likely shed light on key trigger motifs involved in G protein versus 
β -arrestin2 recruitment. Indeed, current inactive-state structures of 
5-HT2C19 and 5-HT1B18, which have both been co-crystallized with
inverse agonists, implicate the conserved P-I-F trigger as a motif 
essential for inactivation and biased signaling.
In our study here, Leu3627.35 in TM7 appears to be an important 
determinant of preference for G protein or β -arrestin2 recruitment, 
as was also implied for κ -opioid receptor biased signaling and for 
other GPCRs35,36,37. In the case of LY266097, which appears to make 
no specific vdW or hydrogen bond contacts with residues in TM7, 
our results with Leu3627.35 mutants suggest that ligand engagement 
with TM7 may operate under strict steric constraints, as was simi-
larly observed in the 5-HT2BR Ala225Gly5.46–methysergide struc-
ture. Notably, hydrophobic contact with Leu3627.35, as in the case 
of LSD, leads to enhanced ligand residence time, and contributions 
from both TM7 and EL2 serve to stabilize ligand residence time. 
In fact, increased ligand residence time has been shown to lead 
to increased β -arrestin2 recruitment over time13, and it appears to 
be a hallmark of β -arrestin-biased ligands at aminergic GPCRs25. 
Further study, however, is required to illuminate subsequent sig-
naling after arrestin recruitment, especially as it relates to G pro-
tein dependence, as shown in one recent study8. Nevertheless, our 
study illuminates that receptor recognition of small substitutions to 
core ligand scaffolds directly modulates G protein versus β -arrestin 
recruitment preferences37.
Identification of critical residue(s) for 5-HT2BR agonist versus 
antagonist recognition and encoding of efficacy is important for 
drug design strategies, which aim to avoid 5-HT2BR activation and 
VHD. On the basis of our previous structural and functional studies 
with 5-HT2BR, it is clear that 5-HT2BR represents an attractive recep-
tor template to clarify the structural features necessary for biased 
signaling as they apply to other class A GPCRs. Insights into the 
structural basis of agonist versus antagonist action at GPCRs are 
essential for the design of safer and more effective medications.
Methods
Methods, including statements of data availability and any asso-
ciated accession codes and references, are available at https://doi.
org/10.1038/s41594-018-0116-7.
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Tris-HCl pH 8.0, 100 mM sodium formate and 30% (vol/vol) polyethylene glycol 
400 (PEG400) for h5-HT2BR-BRIL-1–LY266097; 100 mM Tris-HCl pH 7.4–7.7, 
30–50 mM ammonium tartrate dibasic and 30% (vol/vol) PEG400 for h5-HT2BR-
BRIL-1–lisuride; 100 mM Tris-HCl pH 7.2–8.0, 170–190 mM potassium phosphate 
monobasic and 30% (vol/vol) PEG400 for h5-HT2BR-BRIL-2–methylergonovine; 
and 100 mM Tris-HCl pH 7.3–7.5, 40–100 mM MgCl2 and 30% (vol/vol) PEG400 
for h5-HT2BR(Ala225Gly5.46)-BRIL-3–methysergide. All crystals grew to a 
maximum size of ~70 µ m × 30 µ m × 20 µ m within 3 d and were harvested directly 
from the LCP matrix using MiTeGen micromounts before flash-freezing and 
storage in liquid nitrogen.
Data collection, structure solution and refinement. X-ray data were collected at 
the 23ID-B and 23ID-D beamline (GM/CA CAT) at the Advanced Photon Source 
(Argonne, IL, USA), using a 10-µ m minibeam at a wavelength of 1.0330 Å and 
either a MarMosaic 300 charge-coupled detector (CCD) or an Eiger-16m detector 
(Dectris). Diffraction data were collected by exposing the crystals for 1–3 s to 
unattenuated beam using primary oscillation. Full datasets for each complex were 
assembled from several crystals owing to the rapid onset of radiation decay at such 
high doses. Data were indexed, integrated, scaled and merged using HKL300041, 
and initial phases were obtained by molecular replacement in PHASER42 using 
the 5-HT2BR coordinates from PDB 4IB4 with the ligand, extracellular loops and 
orthosteric residues removed. Refinement was performed with PHENIX43 and 
REFMAC and included extensive use of simulated annealing to remove model 
bias. Density was manually examined, and coordinates were rebuilt in COOT44 
using |2Fo| – |Fc|, |Fo| – |Fc| and omit maps. After refinement, we did not observe 
any Ramachandran outliers in any of the structures: 96.34% and 3.66% (5-HT2BR–
methylergonovine), 95.29% and 4.71% (5-HT2BR(Ala225Gly5.46)–methysergide), 
and 96.7% and 3.3% (5-HT2BR–lisuride) as well as 97.47% and 2.53% (5-HT2BR–
LY266097) of residues were in favored and allowed regions, respectively, as defined 
by Ramachandran statistics. We further observed low Molprobity clash scores of 
4.48, 4.94, 3.77 and 3.97 for 5-HT2BR–methylergonovine, 5-HT2BR(Ala225Gly5.46)–
methysergide, 5-HT2BR–lisuride and 5-HT2BR–LY266097, respectively.
Gq-mediated calcium flux FLIPR assays. Stable cell lines were generated for 
wild-type 5-HT2BR and all of the 5-HT2BR mutants using the Flp-In 293 T-Rex 
Tetracycline-inducible system (Invitrogen, mycoplasma-free). Cell lines were 
maintained in DMEM containing 10% FBS, 10 µ g/ml blasticidin (Invivogen) 
and 100 µ g/ml hygromycin B (KSE Scientific). The day before the FLIPR assay, 
tetracycline-induced cells were seeded into 384-well poly-(l-lysine)-coated 
black plates at a density of 10,000 cells/well in DMEM containing 1% dialyzed 
FBS. On the day of the assay, the cells were incubated with Fluo-4 Direct dye 
(Invitrogen, 20 µ l/well) for 1 h at 37 °C, which was reconstituted in drug buffer 
(20 mM HEPES-buffered Hank’s Buffered Salt Solution (HBSS), pH 7.4) containing 
2.5 mM probenecid. After dye loading, cells were allowed to equilibrate to room 
temperature for 15 min and were then placed in a FLIPRTETRA fluorescence imaging 
plate reader (Molecular Dynamics). Drug dilutions were prepared at 5 × final 
concentration in drug buffer (20 mM HEPES-buffered HBSS, pH 7.4) containing 
a final concentration of 0.1% BSA and 0.01% ascorbic acid. Drug dilutions were 
aliquotted into 384-well plastic plates and placed in the FLIPRTETRA for drug 
stimulation. The drug solutions used for the FLIPR assay were exactly the same as 
those used for the Tango assay. The FLIPRTETRA was programmed to read baseline 
fluorescence for 10 s (1 read/s), and afterward 5 µ l of drug/well was added and 
read for a total of 3 min (1 read/s). Fluorescence in each well was normalized to 
the average of the first ten reads for baseline fluorescence, and then the maximum 
fold increase was determined and calculated as fold change relative to basal levels 
(fold-over-basal). Fold-over-basal was plotted as a function of drug concentration, 
and data were normalized to percent 5-HT stimulation. Data were plotted, and 
nonlinear regression was performed using ‘log(agonist) versus response’ in 
GraphPad Prism 5.0 to yield Emax and EC50 parameter estimates.
β-arrestin2 recruitment Tango assays. Measurement of β -rrrestin2 recruitment 
at 5-HT2BR and its mutants used constructs that contained a TEV protease 
cleavage site and the tetracycline transactivator (tTA) fused to the C terminus 
of the receptor. Assays were designed and performed as previously described45. 
HTLA cells expressing TEV-fused β -arrestin2 (derived from HEK cells and kindly 
provided by R. Axel) were grown and maintained in DMEM containing 10% 
FBS, 5 µ g/ml puromycin and 100 µ g/ml hygromycin B. On the day of transfection, 
medium was removed from the HTLA cells, the cells were washed with PBS, and 
DMEM containing 10% dialyzed FBS and no antibiotics was added. After at least 
1 h, the cells were transfected with the 5-HT2BR- or mutant-encoding constructs 
using a calcium-phosphate precipitation method46. After at least 24 h, medium was 
decanted, and the cells were washed with PBS and detached using trypsin. Cells 
were collected via centrifugation, resuspended in DMEM containing 1% dialyzed 
FBS and plated into poly-(l-lysine)-coated 384-well white clear-bottom cell culture 
plates at a density of 7,000–10,000 cells/well in a total of 40 µ l. The cells were 
incubated at 37 °C and 5% CO2 for at least 6 h before receiving drug stimulation. 
Drug solutions were prepared in drug buffer (20 mM HEPES-buffered HBSS,  
pH 7.4) containing 0.1% BSA and 0.01% ascorbic acid (final concentrations). Drug 
stimulation was performed using the FLIPRTETRA system by dispensing 10 µ l/well. 
Methods
Generation of 5-HT2B receptor constructs. Constructs encoding 5-HT2BR for 
the generation of crystals were based on previously published 5-HT2BR constructs 
in which thermostabilized apocytochrome b562 RIL (M7W, H102I, R106L) from 
Escherichia coli—referred to as BRIL—was fused to intracellular loop 3 (ICL3)38,39 
of the receptor12,13. The 5-HT2BR–LY266097 and 5-HT2BR–lisuride complexes were 
crystallized using a previously crystallized construct (h5-HT2BR-BRIL-1) that 
lacked N-terminal residues 1–35 and C-terminal residues 406–481, contained 
a thermostabilizing Met144Trp3.41 substitution40 and possessed residues Ala1 
to Leu106 of BRIL in place of receptor residues Tyr249 to Val313 of ICL338,39. 
The 5-HT2BR–methylergonovine complex was crystallized by using a different 
previously crystallized construct13 (h5-HT2BR-BRIL-2) that included Val313 but 
that was otherwise identical to h5-HT2BR-BRIL-1. The 5-HT2BR(Ala225Gly5.46)–
methysergide complex (h5-HT2BR-BRIL-3) was generated by QuikChange 
(Agilent) PCR, mutating the sequence for Ala2255.46 to glycine in the h5-HT2BR-
BRIL-2 construct. All constructs also contained a hemagglutinin (HA) signal 
sequence followed by a FLAG tag at the N terminus and a PreScission protease site 
followed by a 10 ×  histidine tag (His tag) at the C terminus to enable purification by 
immobilized metal affinity chromatography.
Expression and purification of the 5-HT2B constructs. High-titer recombinant 
baculovirus (> 109 viral particles/ml) was generated using the Bac-to-Bac 
Baculovirus Expression System (Invitrogen). Recombinant baculovirus was 
obtained by transfecting ~5 µ g of recombinant bacmid into 5 × 105 settled 
Spodoptera frugiperda (Sf9) cells (Expression Systems) in a 12-well plate (Corning) 
using 3 µ l of Cellfectin II Reagent (Invitrogen). After 5–12 h, medium was 
exchanged for 1 ml of Sf-900 II SFM medium (Invitrogen), and the plates were 
incubated for 4–6 d at 27 °C. P0 viral stock was harvested as the supernatant 
and used to generate high-titer baculovirus stock by infection of 40–1,000 ml of 
2 × 106 Sf9 cells/ml and incubation for 3 d. Viral titers were determined by flow 
cytometry analysis of cells that were stained with phycoerythrin (PE)-conjugated 
gp64 antibody (Expression Systems)38. Expression of 5-HT2BR was carried out 
by infection of Sf9 cells at a cell density of 2 × 106 to 3 × 106 cells/ml in ESF921 
medium (Expression Systems) with P1 virus at a multiplicity of infection (MOI)  
of 3–5. Cells were harvested by centrifugation at 48 h after infection, washed in  
PBS and stored at –80 °C until use. Cells were disrupted by thawing frozen cell 
pellets in a hypotonic buffer (10 mM HEPES, 10 mM MgCl2, 20 mM KCl, pH 7.5) 
containing protease inhibitors (500 µ M AEBSF, 1 µ M E-64, 1 µ M leupeptin, 150 nM 
aprotinin). Membranes were purified by repeated centrifugation in a high-osmotic 
buffer (containing 10 mM HEPES, 1 M NaCl, 10 mM MgCl2, 20 mM KCl, pH 7.5)  
to remove soluble and membrane-associated proteins. Purified membranes 
were directly flash-frozen in liquid nitrogen and stored at –80 °C until protein 
purification. Purified membranes were resuspended in a buffer containing 10 mM 
HEPES, 10 mM MgCl2, 20 mM KCl, 150 mM NaCl (pH 7.5) and protease inhibitors 
and were incubated for 1 h at room temperature with 50 µ M methylergonovine 
(Sigma, M2776), methysergide (Sigma, M137), lisuride (Tocris, 4052) or 
LY266097 (Tocris, 4081). After a 30-min incubation in the presence of 2 mg/ml 
iodoacetamide (Sigma), membranes were solubilized in 10 mM HEPES, 150 mM 
NaCl, pH 7.5, 1% (wt/vol) n-dodecyl-β -d-maltopyranoside (DDM, Anatrace),  
0.2% (wt/vol) cholesteryl hemisuccinate (CHS, Sigma), 25 µ M of the indicated 
complex ligand and protease inhibitors for 2 h at 4 °C. Unsolubilized material 
was removed by centrifugation at 150,000g for 30 min, and 15 mM imidazole was 
added to the supernatant. Proteins were bound to TALON IMAC resin (Clontech) 
overnight at 4 °C using approximately 750 µ l of resin for protein purified from  
2 liters of cells. The resin was then washed with 10 column volumes (CVs) of Wash 
Buffer I (50 mM HEPES, 800 mM NaCl, pH 7.5, 0.1% (wt/vol) DDM, 0.02%  
(wt/vol) CHS, 20 mM imidazole, 10% (vol/vol) glycerol and 20 µ M of the indicated 
complexing ligand), followed by 10 CVs of Wash Buffer II (25 mM HEPES, 150 mM 
NaCl, pH 7.5, 0.05% (wt/vol) DDM, 0.01% (wt/vol) CHS, 10% (vol/vol) glycerol 
and 20 µ M of the indicated complexing ligand). Proteins were eluted in 2.5 CVs of 
Wash Buffer II +  250 mM imidazole and concentrated in a Vivaspin 20 concentrator 
with a molecular weight cutoff of 100 kDa (Sartorius Stedim) to 500 µ l;  
imidazole was removed by desalting the protein over PD MiniTrap G-25 columns 
(GE Healthcare). The C-terminal 10 ×  His tag was removed by addition of His-
tagged PreScission protease (GenScript) and incubation overnight at 4 °C. Protease, 
cleaved His tag and uncleaved protein were removed by passing the suspension 
through equilibrated TALON IMAC resin (Clontech) and collecting the flow-
through. 5-HT2BR–ligand complexes were then concentrated to ~30 mg/ml using 
a Vivaspin 500 centrifuge concentrator with a molecular weight cutoff of 100 kDa 
(Sartorius Stedim). Protein purity and monodispersity were tested by analytical 
size-exclusion chromatography.
Lipidic cubic phase crystallization. 5-HT2BR–ligand complexes were reconstituted 
into lipidic cubic phase (LCP) by mixing protein and a monoolein:cholesterol 
mixture at a ratio of 40%:54%:6% by using the twin-syringe method5. 
Crystallization was done on 96-well glass sandwich plates (Marienfeld) in  
50-nl LCP drops that were dispensed from a 10-µ l gas-tight pipette (Hamilton) 
using a handheld dispenser (Art Robbins Instruments) and overlaid with 1 µ l 
of precipitant solution. After optimization, crystals were obtained in 100 mM 
Drug solutions used for Tango assays, which were performed on the same day, were 
exactly the same as those used for FLIPR assays. Plates were incubated at 37 °C 
and 5% CO2 for at least 20–22 h. Afterward, medium was decanted, plates were 
blotted to remove excess medium and 20 µ l/well of BrightGlo reagent (Promega; 
diluted 1:20 in drug buffer) was added. The plate was incubated for 20 min at room 
temperature in the dark before being counted using a Wallac Trilux MicroBeta 
luminescence counter. Relative luminescence units (RLUs) were plotted as a 
function of drug concentration, normalized to percent 5-HT, and analyzed using 
‘log(agonist) versus response’ in GraphPad Prism 5.0.
Phosphoinositide hydrolysis assays. PI hydrolysis assays measuring Gq-mediated 
IP accumulation were performed using a scintillation proximity assay (SPA)9,47. On 
the day before the assay, cells were seeded into 96-well poly-(l-lysine)-coated white 
plates at a density of 40,000–50,000 cells/well in 200 µ l of inositol-free DMEM 
(Caisson Labs) containing 1 µ Ci/well (final concentration) [3H]myo-inositol 
(PerkinElmer) and incubated overnight for 16–18 h at 37 °C and 5% CO2. The next 
day, the label medium was siphoned off and replaced with 200 µ l of inositol-free 
DMEM. Drug stimulation was initiated with addition of 50 µ l of 5 × concentrated 
drug dilutions made up in drug buffer (20 mM HEPES-buffered HBSS, pH 7.4) 
containing 0.1% BSA and 0.01% ascorbic acid (final concentrations). To capture 
IP accumulation, lithium chloride (10 µ l/well; 15 mM final concentration) was 
added 15 min before lysis. The assay was terminated by decanting the medium and 
adding 40 µ l of 50 mM cold formic acid. After overnight incubation at 4 °C, 10 µ l of 
lysates was added to 96-well flexible, clear microplates (PerkinElmer) containing 
75 µ l of 0.2 mg/well RNA-binding yttrium silicate beads (PerkinElmer) and 
incubated for 1–2 h wrapped in foil on a shaker at room temperature. Afterward, 
plates were centrifuged at 300g for 1 min, and radioactivity was measured with a 
Wallac MicroBeta Trilux plate reader (PerkinElmer) using the SPA paralux setting. 
IP accumulation data were plotted as counts per minute (CPM) as a function of 
drug concentration, normalized to percent 5-HT stimulation, and analyzed using 
‘log(agonist) versus response’ in GraphPad Prism 5.0.
Bioluminescence resonance energy transfer arrestin assays. To measure 
5-HT2BR-mediated β -arrestin2 recruitment as measured by BRET1, HEK293T 
cells (ATCC CRL-11268; 59587035; mycoplasma-free) were co-transfected in a 
1:1:15 ratio with constructs encoding human 5-HT2BR with C-terminally fused 
Renilla luciferase (RLuc8), GRK2 and N-terminally Venus-tagged β -arrestin2 in 
DMEM supplemented with 10% dialyzed FBS using TransiT-2020 (Mirus). To 
measure 5-HT2BR-mediated Gq activation via Gq/γ1 dissociation, as assessed by 
BRET2, HEK293T cells in DMEM supplemented with 10% dialyzed FBS were co-
transfected in a 1:1:1:1 ratio with constructs encoding RLuc8 fused at residue 121 
of human Gαq (Gαq-RLuc8), GFP2 fused to the C terminus of human Gγ1 (Gγ1-GFP2), 
human Gβ 1, and either wild-type 5-HT2BR or a mutant using TransiT-2020. After 
at least 18–24 h, transfected cells were plated in poly-(l-lysine)-coated 96-well 
white clear-bottom cell culture plates in DMEM containing 1% dialyzed FBS at a 
density of 30,000–40,000 cells in 200 µ l/well and incubated overnight. The next day, 
medium was decanted, and cells were washed with 60 µ l of drug buffer (1 × HBSS, 
20 mM HEPES, 0.1% BSA, 0.01% ascorbic acid, pH 7.4); then, 60 µ l of drug buffer 
was added per well. For kinetic experiments, plates were incubated at 37 °C for at 
least 20 min before receiving drug stimulation. Afterward, 30 µ l of drug (3 × ) was 
added per well, and the plates were incubated for the designated amounts of time. 
For β -arrestin2 recruitment assays, 10 µ l of the RLuc substrate, coelenterazine 
h (Promega, 5 µ M final concentration) was added per well, and the plates were 
incubated for an additional 15 min to allow for substrate diffusion and immediately 
read for both luminescence at 485 nm and fluorescent eYFP emission at 530 nm for 
1 s/well with a Mithras LB940 instrument. The eYFP/RLuc ratio was calculated for 
each well, and the net BRET1 ratio was calculated by subtracting the eYFP/RLuc 
ratio for each well from the eYFP/RLuc ratio in wells without Venus-β -arrestin2 
present. For Gq/γ1 dissociation assays, 10 µ l of the RLuc substrate coelenterazine 
400a (Nanolight Technology, 5 µ M final concentration) was added per well, and 
the plates were incubated for an additional 10 min to allow for substrate diffusion 
and then immediately read for both luminescence at 400 nm and fluorescent GFP2 
emission at 510 nm for 1 s/well with a Mithras LB940. BRET2 ratios were calculated 
as the ratio of GFP2 fluorescence to either the net BRET1 or BRET2 ratios and were 
plotted as a function of drug concentration using GraphPad Prism 5. Data were 
normalized to percent 5-HT stimulation and analyzed using nonlinear regression 
‘log(agonist) versus response’ in GraphPad Prism 5.0.
Radioligand binding assays. Binding assays were performed using stable Flp-In 
293 T-Rex tetracycline-inducible cell lines for 5-HT2BR or its mutants. Binding 
assays were set up in 96-well plates in standard binding buffer (50 mM Tris, 
10 mM MgCl2, 0.1 mM EDTA, 0.1% BSA, 0.01% ascorbic acid, pH 7.4) using [3H]
LSD (PerkinElmer; specific activity = 76.0–82.2 Ci/mmol) as the radioligand. For 
competitive binding assays, all assays were performed with various concentrations 
of cold unlabeled ligands (1 pM to 10 µ M), [3H]LSD (0.2–0.7 nM) and resuspended 
membranes in a total volume of 225 µ l. Reactions for competition assays were 
incubated for 4 h at 37 °C in a humidified incubator until harvesting. For [3H]LSD 
dissociation assays, assays used at least two or three radioligand concentrations 
(0.3–2.0 nM), and reactions were pre-incubated for 2 h at 37 °C in a humidified 
incubator in a total of 200 µ l/well. To initiate dissociation, 10 µ l of cold excess LSD 
(10 µ M) was added to each well at specific time points ranging from 2 min to 7 h, 
and immediately at time = 0 min plates were harvested. For all assays, nonspecific 
activity was defined as the addition of 10 µ M SB 206553. Plates were harvested 
using vacuum filtration onto 0.3% polyethyleneimine-presoaked 96-well Filtermat 
A (PerkinElmer) and washed three times at 250 µ l/well with cold wash buffer 
(50 mM Tris, pH 7.4). Filters were dried, and scintillation cocktail (Meltilex, 
PerkinElmer) was melted and allowed to cool to room temperature. Afterward, 
filter plates were placed in cassettes and read using a Wallac Trilux Microbeta 
counter (PerkinElmer). Data were analyzed with GraphPad Prism 5.0 using ‘One-
site-homologous’ to yield Kd, ‘One-site-Fit Ki’ to yield Ki or ‘Dissociation-One 
phase exponential decay’ to yield estimates of koff.
Chemistry general procedures. HPLC spectra for all compounds were acquired 
using an Agilent 1200 series system with a diode array detector. Chromatography 
was performed on a 2.1 mm × 150 mm Zorbax 300SB-C18 5-μ m column with water 
containing 0.1% formic acid as solvent A and acetonitrile containing 0.1% formic 
acid as solvent B, at a flow rate of 0.4 ml/min. The gradient program was as follows: 
1% B (0–1 min), 1–99% B (1–4 min) and 99% B (4–8 min). High-resolution mass 
spectra (HRMS) data were acquired in positive-ion mode using an Agilent G1969A 
API-TOF instrument with an electrospray ionization (ESI) source. NMR spectra 
were acquired on a Bruker DRX-600 spectrometer (600 MHz 1H, 150 MHz 13C) or 
a Varian Mercury spectrometer (400 MHz 1H, 100 MHz 13C). Chemical shifts are 
reported in parts per million (p.p.m.) (δ). Preparative HPLC was performed on an 
Agilent Prep 1200 series instrument with the UV detector set to 254 nm. Samples 
were injected into a Phenomenex Luna 75 mm × 30 mm, 5 μ m, C18 column at room 
temperature. The flow rate was 40 ml/min. A linear gradient was used with 10% 
(or 50%) methanol (A) in water (with 0.1% trifluoroacetic acid; TFA) (B) to 100% 
of methanol (A). HPLC was used to establish the purity of target compounds. All 
final compounds had > 95% purity using the HPLC methods described above. 
Synthesis schemes and purification details of the compounds can be found in the 
Supplementary Note.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability. Atomic coordinates and structure factors have been deposited 
in the Worldwide Protein Data Bank (wwPDB) under accession codes 6DRY (5-
HT2BR–methylergonovine), 6DRZ (5-HT2BR(Ala225Gly5.46)–methysergide), 6DRX 
(5-HT2BR–lisuride) and 6DS0 (5-HT2BR–LY266097). Generated and analyzed 
datasets that support the findings of this study are available as source data files or 
from the corresponding authors upon reasonable request. Source data for Figs 1, 2, 
3, 4, 5 are available online.
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